Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65 EUR | 0.00% |
|
+4.00% | +17.12% |
Jun. 21 | DA Davidson Upgrades Prestige Consumer Healthcare to Buy From Neutral, Adjusts Price Target to $93 From $65 | MT |
May. 15 | Sector Update: Health Care Stocks Rise Pre-Bell Wednesday | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.12% | 3.57B | - | ||
+61.53% | 848B | C+ | ||
+38.95% | 627B | B | ||
-3.66% | 363B | C+ | ||
+15.06% | 318B | B- | ||
+9.18% | 299B | C+ | ||
+5.89% | 234B | A+ | ||
+16.53% | 225B | B- | ||
+15.67% | 179B | C+ | ||
+2.47% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PBH Stock
- PBV Stock
- Ratings Prestige Consumer Healthcare Inc.